

Competitive PET Study of the Central Nicotinic Receptors $\alpha 4\beta 2$ in Baboons

Larisa MIHOREANU ^{1,2}

1 Alternatives Sciences Association Bucharest, 13-15 Mihai Eminescu Str. Sector 1, 010374 Bucharest, Romania
2 King's College London, Blood-Brain Barrier Group, Hodgkin Building, Guy's Campus, London, SE1 1UL, UK

Introduction

nAChRs & Cognitive brain functions


The central nicotinic acetylcholine receptors (nAChRs) mediate neurotransmission and a variety of cognitive brain functions like memory, learning, attention, drug addiction; they are involved in Alzheimer's & Parkinson's diseases, epilepsy, schizophrenia and nicotine dependence.

In vivo imaging techniques, like Positron Emission Tomography (PET), offer the possibility to monitor human nAChRs in central nervous system disorders, using a suitable nicotinic radioligand: [18F]Fluoro-A-85380 (2-[18F]fluoro-3-[2(S)-2-azetidylmethoxy]pyridine) a selective agonist of the major subtype of nicotinic receptors in the brain, $\alpha 4\beta 2$.


Aim of the study: investigate the cerebral distribution of the nAChRs $\alpha 4\beta 2$ using a new radioligand, in Papio papio Baboons.

Methods


PET Scanner Ecat Exact HR+ (CTI-Siemens)



The experimental design of a *in vivo* study



[18F] Fluoro A-85380: a new radioligand for the nAChR $\alpha 4\beta 2$



2-[18F] fluoro-3-[2(S)-2-azetidylmethoxy] pyridine


affinity: big for the nAChR $\alpha 4\beta 2$ in the brain
KD 40-50pmol/L

selectivity: no affinity for the R $\alpha 7$, 5HT₂
toxicity: low, 50µg/Kg-with no effect in rodents

Can be used in Humans


Results

Cerebral Kinetics of the ligand 18F-A85380



Results

Radioligand Kinetics in the Thalamus in presence of Nicotine, as competitor



Data Analysis for the Cerebral Kinetics

- Studied in each specific brain region of interest, at precise level of the anatomical structures.
- The kinetics of [18F]Fluoro-A-85380 in a specified region is as a distribution curve obtained from the analysis of the images obtained after the PET.
- The concentration of radioactivity is expressed as a percentage of **the injected dose per milliliter of tissue**

$$\%D.I./mL$$


- The results obtained from the controls are used to obtain the kinetics curve of reference for our specific radioligand.

- The curves were normalised by the value obtained at 80min.
- The calculation of the percentage of the displacement of the tracer by the competitor molecules studied is performed at time T0 + 190 - 200 min, by subtraction of the tracer's concentration curves values obtained in presence of different competitors from the control curve values of the same radioligand, as in the equation:

$$Depl (\%) = (C - D) / C$$

- C and D represent the average values of the tracer fixation in the control study and in presence of competitors where the displacement takes place.

Radioligand Kinetics in the Thalamus in Presence of Competitors



Kinetics of [18F]Fluoro-A-85380 in presence of competitors: nicotine, tobacco and nornicotine.

Six competition studies were performed: four with the nicotine, two with the nornicotine and two with the tobacco.

Two doses of nicotine (0.3 and 0.6 mg) and two doses of nornicotine (0.15 and 0.5 mg) were injected by i.v. to the baboons; the tobacco was given by successive inhalation of 1 cigarette.

Conclusions

- The PET results show that the cerebral distribution of the radioligand is correlated with the localisation of the $\alpha 4\beta 2$ nicotinic receptors in the brain.
- The nicotine, the nornicotine and the cigarette smoke are competing with the radioligand [18F]Fluoro-A-85380 for the same fixation sites of the $\alpha 4\beta 2$ nicotinic receptors.
- The results obtained open a new view on the role of the nornicotine (a nicotine metabolite) on the mechanism induced by the nicotine in the brain.

References

- Perry DC. et al. (1999). *JPET*, **289**(3):1545-1552.
- Dollé F. et al. (1999). *J Med Chem.*, **42**(12):2251-2259.
- Ghosheh OA. et al. (2001). *Drug Metab*, **29**(5):645-51
- Fundamentals of Enzyme Kinetics (1995, 3rd Ed) A. Cornish-Bowden.

Acknowledgements

Acknowledgements go to the French Government for their financial support and to Pr. Carmen Costea who accepted to present this poster.